Sandoz Voluntary Recalls Ranitidine Hydrochloride Capsules Due to Elevated Amount of N-Nitrosodimethylamine in the US

 Sandoz Voluntary Recalls Ranitidine Hydrochloride Capsules Due to Elevated Amount of N-Nitrosodimethylamine in the US

Sandoz Voluntary Recalls Ranitidine Hydrochloride Capsules Due to Elevated Amount of N-Nitrosodimethylamine in the US

Shots:

  • Sandoz recalls all quantities and lots of ranitidine hydrochloride capsules (150/300mg) including 30 count, 60 count and 500 count bottles within expiry to the consumer level due to an elevated amount of impurity of NDMA which is classified as a carcinogen in the US. The recall is being conducted with the knowledge of the US FDA
  • Sandoz will be notifying its distributors and customers via overnight mail, Sandoz web site, and will arrange for the return of all recalled products. Consumers can contact Sandoz at 1-800-525-8747 option # between 8:30 am – 5:00 pm Monday – Friday EST or www.us.sandoz.com regarding any query about the recall
  • Ranitidine Hydrochloride is an oral therapy, indicated for duodenal ulcer, benign gastric ulcer, reflux esophagitis, post-operative peptic ulcer, Zollinger-Ellison Syndrome and other conditions where reduction of gastric secretion and acid output is required

Click here to­ read full press release/ article | Ref: Sandoz | Image: Finazen

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post